March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for the worldwide rights to linerixibat, an experimental treatment for severe
GSK Secures Up To $690M From Alfasigma for Licencing Liver Disease Drug
GSK and Alfasigma Strike Major Licensing Deal for Linerixibat
Overview of the Agreement
March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for the worldwide rights to linerixibat, an experimental treatment for severe itching in patients with a rare liver disease.
About Linerixibat and Target Disease
The drug treats cholestatic pruritus, a relentless internal itch affecting patients with primary biliary cholangitis (PBC), an autoimmune disease where the body's immune system attacks bile ducts in the liver.
Financial Terms of the Deal
Upfront and Milestone Payments
Alfasigma will pay GSK $300 million upfront plus another $100 million upon expected U.S. approval by March 24. It will pay $20 million when European and UK regulators approve the drug.
Sales Milestones and Royalties
GSK is also eligible for up to $270 million in sales milestones and will earn tiered double-digit royalties on worldwide sales from Alfasigma, which already markets treatments for liver diseases across more than 100 countries.
Reporting Credits
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala and Janane Venkatraman)
